Peptides for Fat Loss
Ranked by Clinical Evidence

Evidence tier: The SURMOUNT, STEP, and SCALE RCT programmes collectively enrolled over 30,000 participants — among the largest obesity intervention trials in history. GLP-1 class compounds represent the highest level of clinical evidence for pharmacological fat loss ever assembled.

The highest pharmacological weight loss ever recorded in a controlled clinical trial. Retatrutide's third receptor — glucagon — adds direct thermogenesis, increasing resting caloric expenditure beyond what appetite suppression alone achieves. For researchers seeking the ceiling of fat loss science.

GIP co-agonism adds insulin sensitization and superior fat mobilization over semaglutide. SURMOUNT-1 showed 21% mean body weight reduction — unprecedented for an FDA-approved compound at the time of approval. The highest-efficacy approved option available.

The pioneer of modern metabolic peptide therapy. Semaglutide defined the GLP-1 era with robust safety data from thousands of participants and a well-characterised side-effect profile. The rational first-time choice and the benchmark every newer compound is measured against.

Elevates endogenous GH 4–8× above baseline through synergistic GHRP + GHRH action. Pulsatile GH drives lipolysis in adipose tissue, preferentially sparing lean mass during a caloric deficit. The cornerstone of any stacked recomposition or muscle-preservation protocol on GLP-1 therapy.

GHK-Cu modulates adipokine signalling, lipid metabolism genes, and inflammatory pathways linked to fat distribution and metabolic efficiency. Acts as a supporting compound for protocols targeting systemic metabolic optimisation rather than acute weight loss alone.

Hypothalamic Appetite Signalling

GLP-1 receptors are densely expressed in the arcuate nucleus and paraventricular nucleus of the hypothalamus — the primary appetite regulation centres of the brain. Activation suppresses NPY/AgRP (hunger) neurons and stimulates POMC/CART (satiety) neurons, producing a sustained reduction in caloric intake that does not habituate at therapeutic timescales. This is fundamentally distinct from stimulant-based appetite suppression, which acts via catecholamine release and rapidly desensitises.

Gastric Emptying Delay

GLP-1R activation slows gastric emptying, extending the duration of post-meal satiety signalling and blunting postprandial glucose spikes. This mechanical component of the effect means caloric reduction is reinforced at the gut level — nutrients remain in the stomach longer, peripheral satiety hormones (PYY, CCK) remain elevated longer, and the incentive to eat again is structurally delayed.

Insulin Sensitisation

GLP-1R activation enhances glucose-dependent insulin secretion from pancreatic β-cells and improves peripheral insulin sensitivity. In GIP co-agonist compounds (Tirzepatide, Retatrutide), GIP receptor activation adds an additional insulin sensitisation pathway through adipose tissue, improving energy partitioning toward lean mass and away from fat storage.

Leptin Sensitivity Restoration

Obesity is characterised by leptin resistance — the hypothalamus stops responding normally to leptin's satiety signal despite high circulating levels. GLP-1R agonists partially restore hypothalamic sensitivity to leptin, addressing a root-cause driver of hyperphagia in obese phenotypes. This is one reason GLP-1 compounds produce results that lifestyle interventions cannot — they address neurological signalling dysfunction, not just caloric intake behaviour.

Glucagon Thermogenesis (Retatrutide only)

Retatrutide's third receptor — glucagon — introduces direct thermogenic activity. Glucagon receptor activation in the liver increases glycogenolysis and fatty acid oxidation, and in adipose tissue upregulates uncoupling protein expression, raising resting metabolic rate. No other approved or near-approved compound combines appetite suppression + insulin sensitisation + thermogenesis in a single agent. This is the mechanism responsible for Retatrutide's record 24.2% weight loss.

For researchers targeting maximum weight reduction without added complexity. Retatrutide delivers the highest recorded fat loss through triple-receptor action including direct thermogenesis. Tirzepatide is the approved-pathway alternative with near-equivalent efficacy and the best safety data of the dual-agonist class.

GLP-1 drives the caloric deficit via appetite suppression and gastric emptying delay. Simultaneously, pulsatile GH elevation from Ipamorelin/CJC promotes lipolysis and lean tissue anabolism — directly counteracting the muscle loss that all GLP-1 caloric deficits produce. The recomposition gold standard.

For researchers combining Tier 1 GLP-1 compounds with GH secretagogue therapy to specifically address the lean mass attrition risk. The larger the caloric deficit (and Retatrutide produces very large deficits), the more important GH-driven anabolism becomes. This stack maximises fat loss while minimising muscle loss.